Literature DB >> 22209346

Gastroparesis and Parkinson's disease: a systematic review.

Zaid S Heetun1, Eamonn M M Quigley.   

Abstract

Some of the gastrointestinal (GI) symptoms commonly experienced by patients with Parkinson's disease (PD) have been attributed to gastroparesis; however, the precise prevalence and relevance of gastric emptying delay in PD is unclear. The definition of gastroparesis varies; currently the most widely accepted definition (from the National Institute of Diabetes and Digestive and Kidney Diseases Gastroparesis Clinical Research Consortium) is the presence of appropriate symptoms (including nausea, retching, vomiting, stomach fullness, and inability to finish a meal) for ≥ 12 weeks, together with delayed gastric emptying on scintigraphy and the absence of any obstructive lesions on upper GI endoscopy. In PD patients, gastroparesis has the potential to affect nutrition and quality of life, as well as the absorption of PD medications, including L-dopa. This reduced absorption of L-dopa has implications for the control of the PD motor symptoms for which it is administered. We performed a systematic review of the literature on gastroparesis in PD with the aim of developing an evidence-based approach to its management. Based on this review, we conclude that while gastric emptying has been reported to be frequently delayed in PD, the existing data do not permit definitive conclusions concerning its true prevalence, relationship to the underlying disease process, relevance to PD management, or the optimal therapy of related GI symptoms. Further study of these important issues is, therefore, required.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22209346     DOI: 10.1016/j.parkreldis.2011.12.004

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  42 in total

1.  Mice overexpressing wild-type human alpha-synuclein display alterations in colonic myenteric ganglia and defecation.

Authors:  L Wang; I Magen; P-Q Yuan; S R Subramaniam; F Richter; M-F Chesselet; Y Taché
Journal:  Neurogastroenterol Motil       Date:  2012-07-11       Impact factor: 3.598

2.  Olfactory Function, Eating Ability, and Visceral Obesity Associated with MMSE Three Years after Parkinson's Disease Diagnosis.

Authors:  M Vikdahl; M E Domellöf; L Forsgren; L Håglin
Journal:  J Nutr Health Aging       Date:  2015-11       Impact factor: 4.075

Review 3.  Gut dysfunction in Parkinson's disease.

Authors:  Adreesh Mukherjee; Atanu Biswas; Shyamal Kumar Das
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

Review 4.  Safety and Tolerability of Pharmacotherapies for Parkinson's Disease in Geriatric Patients.

Authors:  Martin Klietz; Stephan Greten; Florian Wegner; Günter U Höglinger
Journal:  Drugs Aging       Date:  2019-06       Impact factor: 3.923

5.  Unchanged gastric emptying and visceral perception in early Parkinson's disease after a high caloric test meal.

Authors:  L Epprecht; S R Schreglmann; O Goetze; D Woitalla; C R Baumann; D Waldvogel
Journal:  J Neurol       Date:  2015-06-06       Impact factor: 4.849

6.  Parkinson's Disease and Its Management: Part 5: Treatment of Nonmotor Complications.

Authors:  George DeMaagd; Ashok Philip
Journal:  P T       Date:  2015-12

7.  Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy.

Authors:  Carsten Buhmann; R Hilker; P Lingor; C Schrader; J Schwarz; M Wolz; H Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2017-02-22       Impact factor: 3.575

Review 8.  Ghrelin and Neurodegenerative Disorders-a Review.

Authors:  Limin Shi; Xixun Du; Hong Jiang; Junxia Xie
Journal:  Mol Neurobiol       Date:  2016-01-26       Impact factor: 5.590

9.  Gastrointestinal manifestations in Parkinson's disease: prevalence and occurrence before motor symptoms.

Authors:  Maria G Cersosimo; Gabriela B Raina; Cristina Pecci; Alejandro Pellene; Cristian R Calandra; Cristiam Gutiérrez; Federico E Micheli; Eduardo E Benarroch
Journal:  J Neurol       Date:  2012-12-21       Impact factor: 4.849

10.  MitoPark transgenic mouse model recapitulates the gastrointestinal dysfunction and gut-microbiome changes of Parkinson's disease.

Authors:  Shivani Ghaisas; Monica R Langley; Bharathi N Palanisamy; Somak Dutta; Kirthi Narayanaswamy; Paul J Plummer; Souvarish Sarkar; Muhammet Ay; Huajun Jin; Vellareddy Anantharam; Arthi Kanthasamy; Anumantha G Kanthasamy
Journal:  Neurotoxicology       Date:  2019-09-07       Impact factor: 4.294

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.